Ramadan is the 9th month of the lunar calendar during which Muslims abstain from food and
drink between dawn and sunset for 30 consecutive days. Ramadan fasting is observed by …

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy an increasing place
in the armamentarium of drugs used for the management of hyperglycaemia and offer new …

Context: Patients with type 2 diabetes mellitus (T2DM) have clinically relevant disturbances
in the effects of the hormone glucose-dependent insulinotropic polypeptide (GIP). Objective …

Inhibition of dipeptidyl peptidase-4 (DPP-4) is an established glucose-lowering strategy for
the management of type 2 diabetes mellitus. DPP-4 inhibitors reduce both fasting and …

摘要背景本研究旨在评价在亚洲主要是中国的2 型糖尿病患者中, 在胰岛素(加用或不加用
二甲双胍) 基础上加用维格列汀治疗的有效性及安全性. 方法在这项为期24 周的多中心 …

Aims To assess, in a real‐world setting, the effect of vildagliptin compared with
sulphonylurea (SU) treatment on hypoglycaemia in Muslim patients with type 2 diabetes …

The dipeptidyl peptidase-4 inhibitor vildagliptin (Galvus®) is approved for use as
monotherapy and combination therapy in type 2 diabetes mellitus. A fixed-dose combination …

There are many advantages of combining incretin therapy [glucagon-like peptide-1 (GLP-1)
receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors] with insulin therapy as a …

Aims To determine the effects of dipeptidyl peptidase‐4 (DPP‐4) inhibition on glucagon
dynamics in patients with insulin‐treated type 2 diabetes (T2D). Methods The study was a …

Introduction Patients with type 2 diabetes (T2DM) are at increased risk for renal impairment
(RI) and, in addition, there is an age-related decline in renal function. At the same time …